Skip to main content

Evidence-Based Supplement Research

Evidence-Based Supplement Research

Vitamin D and Reduced Lymphocytic Genome Damage

Doses used in studies

IU/month: 50,000 (median 50,000, IQR 50,000–50,000) — 1 study

Time to effect

Median: 24.3 months · IQR 24.3 months–24.3 months · Range 24.3 months–24.3 months — Reported in 1 of 1 study

1 of 1 paper

High-dose vitamin D supplementation and prostate cancer progression: a phase II randomised trial in localised prostate cancer cases with intermediate risk of progression (ProsD).
- 2025-12-21
- RCT
- British journal of cancer 134(5)
- - Visalini Nair-Shalliker
  - David P Smith
  - Val Gebski
  - Manish I Patel
  - Mark Frydenberg
  - John Yaxley
  - Robert 'Frank' Gardiner
  - David Espinoza
  - Michael G Kimlin
  - Varinderpal Dhillon
  - Wayne Leifert
  - David Gillatt
  - Henry Woo
  - Krishan Rasiah
  - Nader Awad
  - James Symons
  - Jadon K Wells
  - Hilda A Pickett
  - Michael Fenech
  - Paul H Anderson
  - Bruce K Armstrong
  - Howard Gurney
- PubMed: 41423505
- DOI: 10.1038/s41416-025-03278-w
4 Insights on
- Reduced Lymphocytic Genome Damage
- High evidence
- Clinical
There were declines in some of the lymphocytic CBMN markers in the vitamin D arm
Effect
Neutral
Effect size
Small
Significant
No
Dose
50,000 IU/month orally